Stevanato Group saw its IBD SmartSelect Composite Rating rise to 96 Friday, up from 93 the day before.
Discover The 3 Keys To Successful Stock Investing
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Stevanato Group is currently forming a cup with handle, with a 28.00 buy point. See if the stock can break out in heavy trade at least 40% higher than normal.
The stock has a 94 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 94% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 30% rise in earnings for Q2. Top line growth climbed 19%, up from 9% in the prior quarter. That marks two quarters of increasing revenue gains.
Stevanato Group holds the No. 4 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
